11 completed, 2 recruiting, 2 terminated, 1 active not recruiting. 18 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 18 | Completed 11, Recruiting 2, Terminated 2, Active not recruiting 1, Suspended 1, Unknown 1 |
| Phase 2 | 4 | Completed 3, Unknown 1 |
Follow Hyperpituitarism: new trials by email Literature Review of Hyperpituitarism trials Research Report on Hyperpituitarism
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1 Study to Evaluate the Relative Bioavailability of Octreotide Acetate Tablets(T25) Compared to MYCAPSSA® and The Food Effect on Pharmacokinetics Of Octreotide Acetate Tablets(T25) T25-Fast, Mycapssa, T25-Fed - Acromegaly | Phase 1 | Completed | Triastek (Shanghai) Limited | 18 | 2026-06-25 | 2026-09-16 |
| A Phase 1 Clinical Trial of NTQ6179 Tablets in Healthy Volunteers NTQ6179, NTQ6179 placebo - Acromegaly | Phase 1 | Recruiting | Nanjing Chia-tai Tianqing Pharmaceutical | 56 | 2026-04-23 | 2026-11-03 |
| Study of MAR002 in Healthy Men MAR002, Placebo - Acromegaly | Phase 1 | Recruiting | Marea Therapeutics | 45 | 2025-08-11 | 2026-01-12 |
| A Study on Bioequivalence of Cabergoline Tablets in Human Body Cabergoline tablets test formulation, Cabergoline tablets reference formulation - Hyperprolactinemia | Phase 1 | Active not recruiting | Changchun GeneScience Pharmaceutical Co., Ltd. | 72 | 2025-06-30 | 2025-11-17 |
| A Phase 1 Study of TE-8214 Solution in Healthy Volunteers TE-8214 - SAD, Placebo - Acromegaly | Phase 1 | Completed | Immunwork, Inc. | 32 | 2024-06-18 | 2025-05-20 |
| A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome atumelnant - Cushing Syndrome, Cushing Disease | Phase 1 / Phase 2 | Completed | Crinetics Pharmaceuticals Inc. | 19 | 2023-10-12 | 2026-10-14 |
| A Single-dose Study of Octreotide Injection in Healthy Adult Subjects SYHX2008 injection, Octreotide Acetate Microspheres for Injection injection, Sandostatin ® injection - Acromegaly | Phase 1 | Completed | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 56 | 2023-03-02 | 2023-10-10 |
| A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Debio 4126, Sandostatin LAR, Somatuline ATG - Acromegaly, GEP-NET | Phase 1 | Terminated | Debiopharm International SA | 19 | 2022-05-18 | 2025-11-17 |
| Clinical Guidance for Proper Treatment of Unexplained Resistant Hyperprolactinemia. cabergoline 1.5-2 mg/week).orally daily for 1 month plus health education, cabergoline 1.5-2 mg/week).orally daily for 1 month without health education - Health Education | Phase 1 | Completed | Woman's Health University Hospital, Egypt | 120 | 2020-02-01 | 2023-05-25 |
| Vitamin D Metabolism in Patients With Endocrine Disorders Cholecalciferol 15000 UNT/ML Oral Solution - Pituitary ACTH Hypersecretion, Acromegaly | Phase 1 | Completed | Endocrinology Research Centre, Moscow | 261 | 2019-04-16 | 2022-08-11 |
| Single-dose Study to Evaluate the Absolute Bioavailability and Mass Balance of ONO-5788 ONO-5788, [14C]-ONO-5788 - Acromegaly | Phase 1 | Completed | Ono Pharmaceutical Co., Ltd. | 12 | 2019-02-27 | 2019-11-07 |
| A Four-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-5788 in Healthy Adult Volunteers ONO-5788, ONO-5788 Placebo, Octreotide - Acromegaly | Phase 1 | Terminated | Ono Pharmaceutical Co., Ltd. | 76 | 2018-06-07 | 2019-06-05 |
| Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole Ropinirole - Hyperprolactinemia, Prolactinoma | Phase 1 / Phase 2 | Completed | Columbia University | 16 | 2016-09-16 | 2024-06-04 |
| Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly Lanreotide PRF - Acromegaly | Phase 1 / Phase 2 | Completed | Ipsen | 28 | 2015-03-01 | 2019-04-25 |
| Pharmacodynamics Of Product Octreotide Acetate Lar 30 Mg Compared To Product Sandostatin LAR ® Octreotide acetate LAR, Sandostatin LAR ® (octreotide acetate LAR) 30 MG - Acromegaly | Phase 1 | Suspended | Azidus Brasil | 16 | 2010-03-01 | 2022-11-03 |
| Kisspeptin Administration in the Adult kisspeptin 112-121, GnRH - Hypogonadotropic Hypogonadism, Kallmann Syndrome | Phase 1 | Completed | Massachusetts General Hospital | 256 | 2009-06-23 | 2024-07-31 |
| Preoperative Bexarotene Treatment for Cushing's Disease Bexarotene - Cushing's Disease | Phase 1 / Phase 2 | Unknown | University of Virginia | 6 | 2008-11-01 | 2011-05-30 |
| Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease Pasireotide - Carcinoid Tumor, Acromegaly | Phase 1 | Completed | Novartis Pharmaceuticals | 85 | 2006-06-01 | 2020-12-21 |
Acromegaly (12) · Hyperprolactinemia (4) · Pituitary ACTH Hypersecretion (3) · ACTH Syndrome, Ectopic (1) · Carcinoid Tumor (1) · Cushing Syndrome (1) · Diabetes Mellitus, Type 1 (1) · Gastro-enteropancreatic neuroendocrine tumor (1) · Health Education (1) · Hyperparathyroidism, Primary (1) · Hypogonadism (1) · Kallmann Syndrome (1) · Polycystic Ovary Syndrome (1) · Prolactinoma (1) · Vitamin D Deficiency (1)
Brain Diseases (18) · Central Nervous System Diseases (18) · Endocrine System Diseases (18) · Hypothalamic Diseases (18) · Nervous System Diseases (18) · Pituitary Diseases (18) · Bone Diseases (12) · Bone Diseases, Endocrine (12) · Musculoskeletal Diseases (12) · Neoplasms (4) · Neoplasms by Histologic Type (2) · Neoplasms, Glandular and Epithelial (2) · Adenocarcinoma (1) · Adenoma (1)
Octreotide (4) · Cabergoline (2) · lanreotide (2) · Bexarotene (1) · Gonadotropin-Releasing Hormone (1) · Injections (1) · pasireotide (1) · ropinirole (1)
Ono Pharmaceutical Co., Ltd. (2) · Azidus Brasil (1) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (1) · Changchun GeneScience Pharmaceutical Co., Ltd. (1) · Columbia University (1) · Crinetics Pharmaceuticals Inc. (1) · Debiopharm International SA (1) · Endocrinology Research Centre, Moscow (1) · Immunwork, Inc. (1) · Ipsen (1) · Marea Therapeutics (1) · Massachusetts General Hospital (1) · Nanjing Chia-tai Tianqing Pharmaceutical (1) · Novartis Pharmaceuticals (1) · Triastek (Shanghai) Limited (1)
United States (7) · China (4) · Germany (3) · Netherlands (3) · Belgium (2) · France (2) · Italy (2) · Poland (2) · Russia (2) · Spain (2) · United Kingdom (2) · Australia (1) · Brazil (1) · Canada (1) · Czechia (1)
Atef M Darwish, Prof (1) · Gabrielle Page-Wilson, M.D. (1) · Jan Jaap van Lier, MD (1) · Liudmila Rozhinskaya, MD, PhD (1) · Mary Lee Vance, MD (1) · Shan NA Jing, PhD (1) · Stephanie B Seminara, MD (1) · Terry O'Reilly, MD (1) · Yang NA Lin, PhD (1)
PMID 24800725, PMID 25226293, PMID 31132118, PMID 34664531, PMID 35138562, PMID 37715962, PMID 39965102, PMID 41273106, PMID 42712757
2005 (1), 2014 (1), R21DK112093 (1)